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Epigenetic regulation in anxiety is suggested, but evidence from large studies is needed. We conducted an epigenome-wide association
study (EWAS) on anxiety in a population-based cohort and validated our finding in a clinical cohort as well as a murine model. In the
KORA cohort, participants (n= 1522, age 32–72 years) were administered the Generalized Anxiety Disorder (GAD-7) instrument, whole
blood DNA methylation was measured (Illumina 450K BeadChip), and circulating levels of hs-CRP and IL-18 were assessed in the
association between anxiety and methylation. DNA methylation was measured using the same instrument in a study of patients with
anxiety disorders recruited at the Max Planck Institute of Psychiatry (MPIP, 131 non-medicated cases and 169 controls). To expand our
mechanistic understanding, these findings were reverse translated in a mouse model of acute social defeat stress. In the KORA study,
participants were classified according to mild, moderate, or severe levels of anxiety (29.4%/6.0%/1.5%, respectively). Severe anxiety was
associated with 48.5% increased methylation at a single CpG site (cg12701571) located in the promoter of the gene encoding Asb1
(β-coefficient= 0.56 standard error (SE)= 0.10, p (Bonferroni)= 0.005), a protein hypothetically involved in regulation of cytokine
signaling. An interaction between IL-18 and severe anxiety with methylation of this CpG cite showed a tendency towards significance in the
total population (p= 0.083) and a significant interaction among women (p= 0.014). Methylation of the same CpG was positively
associated with Panic and Agoraphobia scale (PAS) scores (β= 0.005, SE= 0.002, p= 0.021, n= 131) among cases in the MPIP study. In a
murine model of acute social defeat stress, Asb1 gene expression was significantly upregulated in a tissue-specific manner (p= 0.006),
which correlated with upregulation of the neuroimmunomodulating cytokine interleukin 1 beta. Our findings suggest epigenetic regulation
of the stress-responsive Asb1 gene in anxiety-related phenotypes. Further studies are necessary to elucidate the causal direction of this
association and the potential role of Asb1-mediated immune dysregulation in anxiety disorders.
Neuropsychopharmacology advance online publication, 21 June 2017; doi:10.1038/npp.2017.102
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INTRODUCTION
Anxiety encompasses overwhelming feelings of worry and
fear. Fear responsiveness is an evolutionarily hard-wired
reaction to a perceived threat that facilitates life-dependent,
appropriate cognitive and behavioral responses. Pathology is
considered when an individual experiences unfocused worry
and an excessive and uncontrollable overreaction to a stimulus
that is subjectively perceived as menacing (Tyrer and
Baldwin, 2006). The spectrum of anxiety disorders includes
distress- (generalized anxiety disorder) and fear-disorder
clusters (ie, panic disorder, agoraphobia, social phobia) that
are strongly inter-correlated. Recently, a large-scale commu-
nity sample of adolescents confirmed that the general anxiety
disorder (GAD) is a heterogeneous disease that is closely
related to other anxiety disorders (Beesdo et al, 2010).
Anxiety and other stress-related disorders are polygenic
and complex, rendering the search for mechanisms respon-
sible for the onset of anxiety disorders a challenge. As with
most psychiatric diseases, a combination of environmental
and genetic factors shape risk and resilience to these
disorders (Kendler et al, 1995). Besides meaningful psycho-
dynamic and behavioral concepts, extensive psycho-
neurobiological research has contributed significantly to the
understanding of the disease condition. For example, it was
shown that adolescents and adult patients who suffer from
anxiety disorders have impaired, hypo-activation of threat-
safety discrimination (Britton et al, 2013) which involves
maladaptive interactions of the prefrontal cortex in threat
perception with the amygdala and hippocampus, parts of the
limbic system that form fear responses (fight, flight, or
freeze) and emotional memory (Haas and Canli, 2008).
While the neural circuits involved in anxiety responses have
been dissected in detail, much less is known about the
molecular factors contributing to disease.
Genome-wide linkage data and candidate gene as well as
genome-wide association studies have indicated some
promising genetic loci for anxiety disorders (Erhardt et al,
2011, 2012, ; Howe et al, 2016; Smoller, 2016; Webb et al,
2012), however, confirmed hits across large cohorts, as they
now exist for schizophrenia, are missing. As with other
psychiatric disorders, large consortium-based studies will be
necessary to identify reliable associations. Heritability for
anxiety disorders is estimated to range from 30 to 40%,
complemented mostly by individually specific environmental
factors, such as adverse life events, with the possibility of
gene × environment interactions to strongly contribute to
disease risk (Shimada-Sugimoto et al, 2015; Swartz et al,
2017). Epigenetic mechanisms offer a possible molecular
integration of both genetic and environmental factors
(Klengel and Binder, 2015). Epigenetic regulations refer to
mechanisms that alter the accessibility of DNA to transcrip-
tional regulation without affecting the DNA sequence and
may include specific sets of histone modifications as well
methylation (the addition of a methyl (–CH3) group) to
cytosine within cytosine-phosphate-guanine (CpG) dinu-
cleotides. Both genetic and environmental factors, including
adverse life events, have been shown to have an impact on
DNA methylation thus providing a link between these two
potential risk domains.
DNA methylation is mainly tissue-specific, nonetheless,
sites with cross tissue relevance exist. Consequently, many
studies have investigated peripheral tissue, including circulat-
ing blood cells, even though the target disease organ is
different. For a number of psychiatric disorders, including
anxiety disorders, immune-related factors may also contribute
directly to pathogenesis. Genome-wide DNA methylation
patterns in peripheral blood have been used in the search for
novel disease-associated loci in a number of psychiatric
disorders, including schizophrenia, post-traumatic stress-
disorder (PTSD), and depression (El-Sayed et al, 2012;
Nestler et al, 2015). In fact, a recent epigenome-wide
association study (EWAS) in peripheral blood in schizo-
phrenia was able to identify differentially methylated loci that
overlap with previously identified genome-wide significant
single-nucleotide polymorphism (SNP) loci (Montano et al,
2016). So far, however, no large-scale DNA methylation study
for anxiety-related traits has been published.
For this reason the current study was undertaken to
compare genome-wide CpG methylation patterns in indivi-
duals with generalized anxiety disorder vs healthy partici-
pants in a population representative sample of community
dwelling adults. The initial epidemiological findings were
confirmed in an additional clinical cohort and the functional
annotation of the associated sites was extended in a
translational animal model for anxiety and stress-relevant
stimulation. DNA methylation studies in peripheral blood
may thus provide an additional tool to identify molecular
risk markers for anxiety disorders.
MATERIALS AND METHODS
Population-Representative KORA Sample and
Cross-Sectional Study Design
Data were obtained from the KORA (Cooperative Health
Research in the Region of Augsburg) F4 study (2006–2008), a
follow-up study of the fourth KORA survey (S4) conducted
in 1999–2001. The cross-sectional, population-based KORA
S4 study sample was recruited from the city of Augsburg and
the two adjacent counties in the south of Germany (Holle
et al, 2005). The F4 study was restricted to subjects aged 32–
81 years at follow-up. Of the 4261 participants of the S4
survey, 3080 were examined again in the F4 study.
Individuals (n= 1814) were randomly selected for genetic
and epigenetic analyses (Wichmann et al, 2005; Zeilinger
et al, 2013). The assessment of anxiety was based on a self-
administered questionnaire which was sent only to partici-
pants aged 32–72 years (n= 1596). Among them, 1522
individuals (95.4% of those with methylation measurements
and aged 32–72 years) had complete data for dependent and
independent variables and were included in this analysis.
The study has been conducted according to the principles
expressed in the Declaration of Helsinki. Written informed
consent has been given by each participant. The study,
including the protocols for subject recruitment and assess-
ment and the informed consent for participants, was
reviewed and approved by the local ethical committee
(Bayerische Landesärztekammer).
Exposure Assessment in KORA
The Generalized Anxiety Disorder (GAD-7), a 7-item
instrument, was used to assess fear and anxiety based
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symptoms that identify the most important diagnostic
criteria for Generalized Anxiety according to the DSM-IV,
and was assessed by a self-administered questionnaire. This
is a valid and reliable tool applied in both clinical and
research settings with predefined cutoff values that are well-
established to assess anxiety (Spitzer et al, 2006). The scale
ranges from 0 to 21, with suggested cutoffs set to distinguish
no or minimal anxiety (0–4) from mild (5–9), moderate
(10–14), or severe (15–21) anxiety disorder, following Spitzer
et al (2006).
Lifestyle and Clinical Confounders in KORA
Information about daily alcohol intake was gathered in the
personal interview and reported in g/day. Smoking status
included the categories (regular/occasional/former/never
smoker). Standardized measurements of height and weight
were obtained during the physical examination and then
body mass index (BMI= kg/m2) was calculated.
Inflammatory Markers in KORA
Fasting EDTA plasma samples stored at 80 °C were used to
measure concentrations of hsCRP using nephelometry on a
BN II using reagents from Siemens (Eschborn, Germany)
and IL-18 by Elisa technology using the IL-18 test kit from
MBL (Nagoya, Japan). More details are previously published
(Herder et al, 2013). Eighty-six participants were excluded
from this analysis due to missing values; however, the
number of participants with severe anxiety remained the
same. Both, CRP and IL-18 concentrations were approxi-
mately lognormal distributed and therefore log-transformed
to be used as continuous variables.
Array-Based DNA Methylation Analysis in KORA with
Infinium Methylation 450 K
The blood sampling was conducted by the KORA study staff
in Augsburg, Germany. Genomic DNA (1 μg) from 1814
samples was bisulfite converted using the EZ-96 DNA
Methylation Kit (Zymo Research, Orange, CA, USA)
according to the manufacturer’s protocol, with the
alternative incubation conditions recommended when using
the Illumina Infinium Methylation Assay. Genome-wide
DNA methylation (n= 485 000 CpG sites) was assessed using
the Illumina HumanMethylation450 BeadChip as described
elsewhere (Pfeiffer et al, 2015). The percentage of methyla-
tion of a given cytosine is reported as a β-value, which is a
continuous variable between 0 and 1, corresponding to the
ratio of the methylated signal over the sum of the methylated
and unmethylated signals plus an offset of 100. M-values
were calculated as the binary logit of the corresponding β-
value. Serum composition of six white blood cell types were
estimated using 473 of the 500 most cell-specific CpG sites
present on the 450k array based on the protocol proposed by
Houseman et al (2012). The estimated blood cell types
include CD3+ CD8+ T-lymphocytes, CD3+ CD4+ T-lympho-
cytes, CD56+ Natural Killer cells, CD19+ B-lymphocytes,
CD14+ monocytes, and CD15+ granulocytes.
Data Pre-Processing and Initial Quality Assessment in
KORA
GenomeStudio (version 2011.1) with methylation module
(version 1.9.0) was used to extract the raw methylation data
generated by BeadArray Reader. Data were preprocessed
using R version 3.0.1 (http://www.r-project.org/). All details
for preprocessing and references for R packages used in this
study are provided in Supplementary text and Supplemen-
tary Table 1. Probes with signals from less than three
functional beads and probes with a detection p-value40.01
were defined as low-confidence probes. Potential batch or
plate effects were accounted for in the regression analyses
(see under ‘Statistical analyses’ below).
MPIP Case–Control Study
The replication sample was derived from patients from the
anxiety disorders outpatient unit and control subjects
recruited at the Max Planck Institute of Psychiatry (MPIP)
in Munich (Erhardt et al, 2011). Panic disorder was
diagnosed using the Structural Clinical Interview for DSM
IV (SCID). All patients included in the current analyses were
not taking any psychotropic medications. In all patients,
severity of panic symptoms was assessed with the Panic and
Agoraphobia scale (PAS) (Bandelow, 1995). Control subjects
were recruited from a Munich-based community sample
after verifying for the absence of axis I psychiatric disorders
using the Munich version of the Composite International
Diagnostic Interview (M-CIDI) (Wittchen, 1997). All sub-
jects were Caucasian and provided written informed consent.
Procedures were approved by the Ethics Committee of the
Ludwig Maximilians University, Munich, Germany, in
accordance with the Declaration of Helsinki.
DNA Methylation Arrays in the MPIP Case–Control
Study
Genomic DNA was extracted from peripheral blood using
the Gentra Puregene Blood Kit (Qiagen). DNA quality and
quantity was assessed by a NanoDrop 2000 Spectro-
photometer (Thermo Scientific) and Quant-iT Picogreen
(Invitrogen). Genomic DNA was bisulfite converted using
the Zymo EZ-96 DNA Methylation Kit (Zymo Research) and
Table 1 Population Description in KORA F4 (n= 1522)
Characteristics Distribution
Male sex (n= 734, %) 48.2
Age (years)a 58.6 (7.5)
Smoking (n= 214, %) 14.1
Alcohol intake (g/day)b 7.9 (22.9)
BMI (in kg/m2)a 28.0 (4.8)
GAD-7 Score
No/minimal anxiety (0–4) (n= 961, %) 63.1
Mild (5–9) (n= 448, %) 29.4
Moderate (10–14) (n= 91, %) 6.0
Severe (15–21) (n= 22, %) 1.5
aMean (standard deviation).
bMedian (interquartile range).
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DNA methylation levels were assessed for 4480 000 CpG
sites using the Illumina HumanMethylation450 BeadChip
array. Hybridization and processing was performed accord-
ing to the instructions of the manufacturer.
Quality control of methylation data including intensity
read outs, normalization, cell type composition estimation,
β- and M-value calculation were done using the Bioconduc-
tor R package minfi (version 1.10.2). Failed probes were
excluded based on a detection p-value larger than 0.01 in
450% of the samples (n= 236 probes). X chromosome, Y
chromosome, and nonspecific binding probes were removed
(Chen et al, 2013). We also excluded probes if SNPs were
documented in the interval for which the Illumina probe is
designed to hybridize. We also removed probes if they were
located close (10 bp from query site) to an SNP which had a
minor allele frequency of ⩾ 0.05. The data were then
normalized with functional normalization (Fortin et al,
2014), an extension of quantile normalization included in the
R package minfi. Batch effects were identified by inspecting
the association of the first principal component of the
methylation levels with bisulfite conversion plate, well, slide,
slide row, and array using linear regression and visual
inspection of PCA plots using the Bioconductor R package
shinyMethyl (version 0.99.3). In order to remove batch
effects, the Empirical Bayes' (EB) method ComBat was used.
Murine Model of Acute Social Defeat Stress and Gene
Expression in Mouse Blood
To examine whether the Asb1 gene is responsive to acute
stress exposure, we used an acute model of social defeat
stress in mice, which is relevant for anxiety-related
phenotypes (Campos et al, 2013). Adult C57BL/6N male
mice (3–4 months old) were exposed to acute social defeat
stress as previously described (Wang et al, 2013). Briefly,
mice were divided into a control (n= 7) and a stress (n= 9)
group. Stressed mice were introduced into the home cage of
an aggressive CD1 resident mouse for 5 min. Mice were
allowed to interact without any interference from the
experimenter. In the case that an animal was injured, the
experimenter intervened immediately and the mouse was
excluded from analysis. Control mice were allowed to
explore an empty novel cage, identical to the resident cage,
for 5 min. Exactly 4 h following stress/control exposure, mice
were anesthetized with isoflurane and killed. Trunk blood
was harvested to assess levels of corticosterone (in order to
validate the stress paradigm) as well as to assess gene
expression using the PAXgene method.
For assessment of gene expression, 250 μl of trunk blood
was placed in PAXgene Blood RNA Tubes (PreAnalytiX).
RNA sample quality was qualitatively analyzed using
capillary gel electrophoresis chip (RNA 6000 Nano Kit;
Agilent, Boeblingen, Germany). RNA samples of sufficient
quality (RIN⩾ 7.5) were then processed with the Illumina
TotalPrep-96 RNA Amplification Kit (Ambion, Austin, TX,
USA) and hybridized onto MouseWG-6 v2 Expression
BeadChips (Illumina, San Diego, CA, USA).
For corticosterone measurements, trunk blood was col-
lected in EDTA-coated microcentrifuge tubes (Kabe Labor-
technik, Nuembrecht-Elsenroth, Germany). Plasma was
isolated following centrifugation at 6000 g at 4 °C for
15 min. A commercially available radioimmunoassay kit
with 125I-labeled anti-corticosterone antibody was used to
determine plasma corticosterone levels (MP Biomedicals,
Solon, OH, USA; sensitivity 12.5 ng/ml).
Statistical Analyses
KORA study. To assess unadjusted associations between
generalized anxiety categories and characteristics, chi-squared
tests, and F-test or Kruskal–Wallis tests were performed for
associations with categorical and continuous characteristics,
respectively. To assess adjusted associations between general-
ized anxiety and methylation, that is, taking potential
confounders into account, linear mixed effects models were
used with methylation M-values as response variable, anxiety
as exposure variable and sex, age, and white blood cell
proportions based on constrained projection (Houseman et al,
2012) as additional covariates to adjust for potential
confounding. In KORA, sensitivity analyses were conducted
with BMI, smoking, and alcohol consumption included as
additional covariates. KORA F4 samples were processed on 20
96-well plates in nine batches; plate and batch effects were
investigated using principle component analysis and eigenR2
analysis. The plate variable explained 4.8% (F4) of variance in
the DNA methylation data. Consequently, plate was included
as a random effect in the analyses. This approach was applied
to individuals categorized by the GAD-7 anxiety instrument
and mild, moderate, or severe anxiety were each compared to
no or minimal anxiety. We did not use the GAD-7 score as a
continuous variable as this approach would require an
assumed linear relation between anxiety and methylation;
nonetheless, our analyses showed a similar methylation
pattern for the lowest three anxiety categories and a
comparatively higher M-value for the severe anxiety category.
Effect estimates are given as β coefficient with standard error
(SE) drawn from the linear mixed effects models comparing
mean M-values of mild, moderate, or severe anxiety to the
reference category no or minimal anxiety.
Analyses that considered the influence of inflammatory
markers on the observed association between level of anxiety
and methylation were run using dummy variables for each
anxiety level in order to model the full cohort. Four CpG sites
were assessed (cg12701571, cg21650243, cg00708580, and
cg14380745) to test for an interaction between anxiety level
and inflammation on methylation of the Asb1 gene. Finally,
adjusted mean levels of inflammatory markers were assessed
in sex-stratified analyses of participants with severe vs no or
minimal anxiety. Generalized linear models included age,
BMI, smoking status, and alcohol consumption.
We used M-values as the outcome in the linear mixed
effects models, since it shows better statistical ability
compared to β-values and a normal distribution can be
assumed (Du et al, 2010). The nlme package in R was used to
run the linear mixed effects models over the 450K array and
proc glm and proc mixed in SAS9.4 (Cary, NC) were used to
run the inflammatory marker analyses.
For those CpG sites which were significantly associated
with methylation M-values, potential differences in the
association between men and women was assessed with an
‘interaction model’ by adding respective interaction terms to
the model described above and estimating the respective
p-values for interaction. An analysis stratified by sex was
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then performed to obtain the effect estimates for males and
females separately.
The statistical package R version 3.0.1 was used to run the
EWAS, and SAS 9.2 (NC, USA) for Windows was used for
the specific sub-analyses. p-Values were assessed as un-
corrected and corrected for multiple testing by the Bonfer-
roni approach (significance level 0.05/441,552–1.1E-07).
MPIP anxiety study. A linear regression model was fitted
for cg12701571 with the batch corrected M-values after
ComBat to test for a case vs control difference and for the
association of methylation levels with anxiety symptoms
within cases. Sex, age, and cell composition (Houseman et al,
2012) were included as covariates in all regression models.
Murine model of acute social defeat stress. Data were
analyzed using R 3.2 (used package: beadarray) and Omics
Explorer 3.1 (Qlucore). Values are presented as technical
batch-corrected residuals.
RESULTS
Demographic, Biomedical and Psychological
Characteristics of the KORA F4 Population
Table 1 gives an overview about the demographic, lifestyle,
and clinical characteristics of the study population
(n= 1522). Men and women were almost equally distributed
(48.2 and 51.2%); mean age was 58.6 years (standard
deviation 7.5, range 32–72 years).
Approximately one-quarter of the study participants were
classified with mild anxiety (26.2/32.5% for men/women),
3.5/8.3% with moderate, and 1.6/1.3% with severe anxiety.
Anxiety was more pronounced in women than in men
(po0.001). Age and anxiety were not significantly associated
in the KORA cohort (p-value 0.867). Moreover, no
significant associations were found for BMI, smoking,
alcohol use, or white blood cell count with anxiety
(Supplementary Table 2). The overall p-value for anxiety ×
smoking was 0.47, trend test 0.18. Even testing only severe
against no/minimal was not NS (p= 0.22). The distributions
of white blood cell composition were rather similar in the
four anxiety categories; p-values were between 0.020 (natural
killer cell) and 0.476 (B cell) subsets indicating no significant
association after Bonferroni correction (adjusted p = 0.05/6
= 0.008).
Increased CpG Methylation in the Promoter Region of
Asb1 Associates with Severe Anxiety in the KORA Study
We analyzed DNA methylation to identify CpG sites
associated with severe, moderate, or mild anxiety compared
to healthy participants, that is, participants with no or
minimal anxiety. No significant association was found for
mild or moderate anxiety. However, in comparisons between
severe and no or minimal anxiety, we identified a single CpG
site (cg12701571) in the promoter region of the ankyrin
repeat and SOCS box protein 1 (Asb1) gene located on
chromosome 2q37, with differential methylation levels after
conservative correction for multiple testing (p⩽ 1E-07)
throughout the genome.
Table 2 presents the detailed effect estimates calculated for
each of the anxiety categories with uncorrected and corrected
p-values. The increase in methylation M-values at the CpG
cg12701571 for severe compared to no or minimal anxiety
was 0.56 (SE 0.10, p-value Bonferroni= 0.005). This differ-
ence remains significant even if corrected further for the
number of comparisons (p-value after Bonferroni correction
of 0.015 (= 0.005 × 3). A sensitivity analysis adjusted
additionally for lifestyle factors (BMI, smoking, and alcohol)
revealed very similar estimations for cg12701571 (β-coeffi-
cient= 0.56, SE= 0.10, p-value Bonferroni= 0.005). In two
other sites in the same region (cg08341874 and cg21593923),
borderline significant associations with anxiety was also
observed (p-values 0.041 and 0.048). These associations of
anxiety with cg08341874 and cg21593923 lost significance
after lifestyle factors were taken into account. Investigation
of genetic confounding was carried out to identify whether
the observed associations between anxiety and methylation
levels were due to SNPs in the Asb1 region (Figure 1). We
tested all SNPs in the Asb1 region for association with DNA
methylation levels and anxiety in the KORA F4 data set.
None of the tested SNPs were nominally associated (po0.05)
with either anxiety or methylation.
To display the actual methylation values and differences,
the unadjusted median β-value methylation for each anxiety
category and their %-change compared to no or minimal
anxiety are additionally provided and showed a %-change in
median β-value methylation of 48.5%. A stratified analysis
Table 2 Association of Anxiety and cg12701571 Asb1 (n= 1522) Estimated by Linear Mixed Effects Model and Unadjusted Median β-Value
Methylation with %-Change Compared to No or Minimal Anxiety in KORA F4
Anxiety category β-coefficient SE uncorrected p-Value uncorrected p-Value Bonferroni Median β-value Median %-change in β-value
No or minimal Ref. — — — 0.0571 Ref.
Mild − 0.0683 0.0258 0.008 1.000 0.0556 − 2.6
Moderate 0.0635 0.0500 0.204 1.000 0.0571 0.1
Severe 0.5585 0.0970 1.04E-8 0.005 0.0848 48.5
The β-coefficients with respective standard error (SE) estimated by a linear mixed effects model for the association of anxiety (explanatory variable) and M-value
methylation (response) are shown for a model adjusted for sex, age, estimated proportions of blood cell types as well as experimental plate additionally included as
random effect.
Median β-coefficient values and median %-change in β-value are shown unadjusted to give an impression of the magnitude of the differences in methylation over the
anxiety categories.
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revealed that the effect of increased methylation on this CpG
site was more pronounced for women (0.683 (SE 0.148),
p-value o0.0001) as compared to men (0.419 (SE 0.130),
p-value 0.0013) who suffered from severe anxiety; however,
this sex-specific interaction was not significant (p-value for
interaction 0.176).
We performed a multinomial logistic regression using the
M-values of cg12701571 as exposure, anxiety as outcome
(with no or minimal as reference), and adjustment for age,
sex, and white blood cell proportions. This analysis revealed
similar findings with a significant association for having
severe compared to no or minimal anxiety (Supplementary
Table 3); the ORs for one unit increase of the M-value was
6.56 (95% CI 3.00–14.32, p-value o0.0001).
An Interaction Between IL-18 and Anxiety is Associated
with Asb1 Methylation
A tendency towards a significant interaction between IL-18
and severe anxiety on methylation changes at CpG site
cg12701571 was observed in the total population (p= 0.08)
and amoung women, a significant interaction was observed
(p= 0.014) (see Table 3a). Interestingly, one of the other CpG
sites (cg21650243) upstream of this CpG of interest showed
significant interactions with IL-18 levels in mildly anxious
participants (total, p= 0.052; women p= 0.007) but here,
mild anxiety was inversely associated with methylation, in
the total population and in women (Table 3b). Adjusted
mean values of IL-18 were significantly reduced in severely
anxious women compared to those with minimal to no
anxiety (Table 4).
Models that accounted for CRP levels showed opposing
estimated effects for mild and severe anxiety on the
methylation of cg cg12701571. In the total population as well
as for both women and men, severe anxiety showed a positive
association with the methylation of this CpG site whereas mild
anxiety was negatively associated with methylation of this site,
predominantly in women (Table 3a). Changes in cg21650243
methylation were not influenced by anxiety level with
adjustment for CRP (Table 3b).
Asb1 Methylation is Associated with Panic Symptom
Severity in the MPIP Study
Using Illumina 450K DNA methylation array data for
cg12701571, we then examined whether these findings
replicated in the independent MPIP study. We observed no
differences in cg12701571 methylation levels between patients
and controls (β= 0.037, SE= 0.025, p= 0.146, Total n= 300).
However, within cases, and after controlling for age, sex, and
blood cell composition, we observed a significant positive
association of cg12701571 methylation levels with PAS scores
(β= 0.005, SE= 0.002, p= 0.021, n= 131) (Figure 2). Three
other CpG sites showed significant differences between panic
cases and controls (cg21650243: β= 0.323, SE= 0.162,
p= 0.047; cg00708580: β= 0.490, SE= 0.191, p= 0.011;
cg14380745: β= 0.477, SE= 0.238, p= 0.046).
Effects of Acute Social Defeat Stress on Asb1 Expression
Levels in a Murine Model
Like other stress-related phenotypes, anxiety disorders have
been associated with DNA methylation changes in stress-
responsive genes (Klengel et al, 2013; Zannas et al, 2015).
Thus, it is plausible that the Asb1 methylation changes,
which we observed in subjects with severe anxiety, could
be attributed to the responsivity of the Asb1 gene to
stress exposure. To address this hypothesis, we compared
Asb1 mRNA levels in the peripheral blood of adult mice
exposed to acute social defeat stress (N= 9) with control
(non-stressed) mice (N= 7). The effectiveness of this
stress paradigm to elicit a stress response was confirmed
by the increased plasma corticosterone (CORT) levels in
response to stress (CORTcontrol= 24.81 vs CORTstress= 71.39:
p= 0.017). Among the four probes covering Asb1 in our
gene expression array data, two probes showed significant
stress-induced upregulation (ILMN_2430887: p= 0.006;
ILMN_1233302: p= 0.016), and ILMN_2430887 remained
significant after Bonferroni correction for multiple compar-
isons (adjusted p= 0.05/4= 0.013; Figure 3).
To understand whether the response of Asb1 to stress
is tissue-specific, we further examined if stress had a
similar effect on the Asb1 expression levels measured with
the ILMN_2430887 probe in the brain amygdala, hippo-
campus, prefrontal cortex, and hypothalamus. Asb1 expres-
sion was not responsive to stress in any of these brain
regions (p40.05). These findings demonstrate Asb1 shows
tissue-specific response to stress in the mouse peri-
pheral blood. Because ASB1 belongs to the SOCS family of
proteins that are thought to play important roles in
inflammation (Elliott and Johnston, 2004), we then exam-
ined whether Asb1 levels correlate with the expression of the
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Figure 1 Genetic map of the Asb1 gene locus on human chromosome 2 indicating the CpG and SNP locations under investigation. From http://www.ncbi.
nlm.nih.gov/gene/51665.
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proinflammatory cytokines interleukin-6, tumor necrosis
factor, and interleukin 1 beta (IL-1β). Among these, only
the IL1b gene was expressed above background in our
mouse blood arrays. IL1b expression robustly correlated with
Asb1 mRNA levels (r= 0.567, p= 0.022) and was signifi-
cantly induced by stress exposure (po0.001). Together,
these findings show that Asb1 is associated with a stress-
induced proinflammatory gene expression profile in
peripheral blood.
DISCUSSION
This is the first large-scale, population-based EWAS in
anxiety published to date, and demonstrates increased
methylation in the promoter region of the Asb1 gene with
severe symptoms of anxiety in participants from the KORA
Study in Augsburg (Southern Germany). Moreover, this
finding of anxiety-related hyper-methylation was supported
in a clinical sample of patients with anxiety symptoms
derived from the Anxiety Disorders Outpatient Clinic of the
Max Planck Institute of Psychiatry (MPIP) (Erhardt et al,
2011). The Asb1 transcript was shown to be responsive to
acute social defeat stress in mice specifically in peripheral
blood, suggesting that ASB1 regulation may be related to
environmental risk factors for anxiety.
In both cohorts, more severe anxiety symptoms were
associated with an increased methylation of a single CpG,
cg12701571. This CpG is located upstream of the transcrip-
tion start site of Asb1 within a site showing histone marks
(H3K27 acetylation) indicative of an active enhancer. At the
same location, chromatin-histone immune precipitation
studies indicate binding of the zinc-finger transcription
factors Early Growth Response (EGR) 1, EGR2, EGR3, and
Table 3a Linear Mixed Effects Models of Cytokine and Anxiety Associations with cg12701571 CpG Methylation in KORA F4
Total Men Women
Estimate SE p-Value Estimate SE p-Value Estimate SE p-Value
CRP
Model 1
Mild anxiety − 0.139 0.058 0.017 − 0.018 0.083 0.826 − 0.212 0.081 0.009
Moderate anxiety 0.011 0.112 0.925 0.005 0.195 0.980 − 0.044 0.138 0.751
Severe anxiety 0.691 0.216 0.001 0.657 0.284 0.021 0.695 0.322 0.031
Log CRP 0.015 0.025 0.535 0.030 0.035 0.396 0.008 0.035 0.831
Model 2
Mild anxiety − 0.145 0.060 0.015 − 0.019 0.084 0.820 − 0.224 0.084 0.008
Moderate anxiety 0.017 0.116 0.882 − 0.016 0.197 0.936 − 0.011 0.145 0.938
Severe anxiety 0.814 0.230 0.000 0.790 0.306 0.010 0.837 0.343 0.015
Log CRP 0.014 0.031 0.646 0.029 0.042 0.493 0.004 0.045 0.923
Mild × Log CRP 0.026 0.055 0.638 0.003 0.082 0.968 0.047 0.075 0.532
Moderate× Log CRP − 0.023 0.096 0.812 0.104 0.154 0.497 − 0.098 0.124 0.431
Severe× Log CRP − 0.360 0.235 0.125 − 0.317 0.266 0.234 − 0.548 0.459 0.233
IL-18
Model 1
Mild anxiety − 0.143 0.058 0.015 − 0.022 0.083 0.788 − 0.213 0.081 0.009
Moderate anxiety 0.012 0.113 0.913 0.008 0.195 0.969 − 0.047 0.140 0.737
Severe anxiety 0.683 0.216 0.002 0.672 0.285 0.019 0.691 0.324 0.033
Log IL-18 − 0.070 0.065 0.280 − 0.134 0.098 0.171 − 0.019 0.087 0.829
Model 2
Mild anxiety − 0.888 0.780 0.256 − 0.452 1.249 0.717 − 0.942 1.050 0.370
Moderate anxiety 0.067 1.496 0.965 − 2.513 3.204 0.433 0.965 1.768 0.585
Severe anxiety 4.523 2.226 0.042 1.492 4.483 0.739 8.948 3.373 0.008
Log IL-18 − 0.096 0.084 0.251 − 0.169 0.123 0.168 − 0.020 0.116 0.865
Mild × Log IL-18 0.131 0.137 0.338 0.074 0.215 0.731 0.130 0.187 0.488
Moderate× Log IL-18 − 0.010 0.262 0.971 0.434 0.551 0.431 − 0.180 0.312 0.565
Severe× Log IL-18 − 0.689 0.397 0.083 − 0.139 0.760 0.855 − 1.577 0.640 0.014
Linear mixed effects model for the association of inflammatory markers (CRP top, IL-18, bottom), anxiety (explanatory variable using dummy variables for mild moderate
and sever anxiety) and M-value cg12701571 methylation (response) are shown for a model adjusted for sex, age, estimated proportions of blood cell types as well as
experimental plate additionally included as random effect (Model 1). Model 2 included interaction terms for anxiety level and cytokine. Statistical significance at po0.05 is
indicated in bold.
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EGR4. The location of this CpG is suggestive of a possible
functional role in transcriptional regulation of Asb1.
The Asb1 gene is located on chromosome 2q37, and
encodes a protein with 335 amino acids. The ASB1 protein is
a member of the ankyrin repeat and SOCS box-containing
(ASB) family of proteins and is expressed in a number of
tissues, including blood cells and brain. The methylation at
this specific CpG shows some trend for a positive correlation
between blood and the tissue from the prefrontal cortex with
r= 0.209 and p= 0.07 (http://epigenetics.essex.ac.uk/blood-
brain/?probenameg= cg12701571).
While the ASB protein family (1–18) is the largest class of
SOCS box proteins, they remain relatively uncharacterized
(Muniz et al, 2013). ASB1 associates with several cullin-
associated neddylation proteins that are involved in the
targeted ubiquitin degradation pathways (Andresen et al,
2014). The ASB1 protein contains ankyrin repeats that
provide scaffolding support and facilitate structure in
neuronal tissue and have been shown to be involved in
neurogenesis and neuroprotection (Leussis et al, 2012). In
muscle, ankyrin repeat proteins are involved in stress and
injury-induced repair and regeneration (Miller et al, 2003).
Another ankyrin repeat gene ANK3 has been associated in a
GWAS with bipolar disorder (Leussis et al, 2012) and a
genetic polymorphism in ANK3 was recently identified in
PTSD patients (Logue et al, 2013). Furthermore, ankyrins as
cytoskeletal adaptor proteins interact with sigma-1 receptors,
which are unique endoplasmic reticulum proteins that have
been implicated in anxiety and depressive-like memory
alterations in knockout mouse models (Chevallier et al,
2011).
The other major functional component of ASB1 is the
SOCS box which is known to partner with the elongin B and
C complexes and thereby also regulate protein turnover by
targeting proteins for ubiquitination (Alexander et al, 1999).
SOCS proteins have cytokine suppressor functions (Krebs
Table 3b Linear Mixed Effects Models of Cytokine and Anxiety Associations with cg21650243 CpG Methylation in KORA F4
Total Men Women
Estimate SE p-Value Estimate SE p-Value Estimate SE p-Value
CRP
Model 1
Mild anxiety 0.015 0.016 0.358 − 0.002 0.024 0.933 0.023 0.022 0.296
Moderate anxiety − 0.007 0.032 0.828 − 0.020 0.059 0.740 − 0.007 0.037 0.847
Severe anxiety − 0.042 0.060 0.484 0.045 0.084 0.596 − 0.139 0.086 0.108
Log CRP 0.006 0.007 0.371 − 0.002 0.010 0.852 0.014 0.009 0.149
Model 2
Mild anxiety 0.019 0.017 0.246 − 0.001 0.025 0.981 0.031 0.022 0.163
Moderate anxiety − 0.012 0.032 0.713 − 0.017 0.060 0.781 − 0.019 0.039 0.617
Severe anxiety − 0.058 0.065 0.369 0.008 0.091 0.926 − 0.126 0.092 0.172
Log CRP 0.010 0.009 0.259 − 0.001 0.012 0.954 0.021 0.012 0.081
Mild × Log CRP − 0.019 0.015 0.213 − 0.007 0.024 0.774 − 0.033 0.020 0.103
Moderate× Log CRP 0.018 0.027 0.507 − 0.021 0.046 0.653 0.035 0.033 0.287
Severe × Log CRP 0.044 0.066 0.501 0.086 0.079 0.275 − 0.052 0.123 0.672
IL-18
Model 1
Mild anxiety 0.014 0.016 0.379 − 0.005 0.025 0.850 0.023 0.022 0.286
Moderate anxiety − 0.008 0.032 0.792 − 0.018 0.059 0.757 − 0.009 0.038 0.821
Severe anxiety − 0.044 0.061 0.468 0.047 0.084 0.579 − 0.142 0.087 0.102
Log IL-18 − 0.013 0.018 0.461 − 0.025 0.029 0.387 − 0.012 0.023 0.621
Model 2
Mild anxiety 0.438 0.218 0.045 − 0.108 0.374 0.773 0.780 0.280 0.006
Moderate anxiety − 0.541 0.420 0.198 − 0.638 0.981 0.516 − 0.463 0.475 0.330
Severe anxiety − 0.582 0.622 0.350 − 0.611 1.325 0.645 0.319 0.904 0.724
Log IL-18 0.003 0.023 0.902 − 0.036 0.036 0.321 0.030 0.031 0.333
Mild × Log IL-18 − 0.075 0.038 0.052 0.018 0.064 0.782 − 0.135 0.050 0.007
Moderate× Log IL-18 0.093 0.074 0.204 0.106 0.168 0.527 0.080 0.084 0.339
Severe × Log IL-18 0.097 0.111 0.383 0.112 0.225 0.618 −0.086 0.172 0.618
Linear mixed effects model for the association of inflammatory markers (CRP top, IL-18, bottom), anxiety (explanatory variable using dummy variables for mild moderate
and severe anxiety) and M-value of cg21650243 methylation (response) are shown for a model adjusted for sex, age, estimated proportions of blood cell types as
well as experimental plate additionally included as random effect (Model 1). Model 2 included interaction terms for anxiety level and cytokine. Statistical significance at
po0.05 is indicated in bold.
Anxiety associated epigenetic regulation of Asb1
RT Emeny et al
8
Neuropsychopharmacology
and Hilton, 2001) and important roles in inflammation,
allergy, and homeostasis (Elliott and Johnston, 2004). A link
between SOCS proteins and moderation of inflammatory
responses is well-established (Boosani and Agrawal, 2015;
Marzi et al, 2016), yet the role of inflammatory markers in
fear-based disorders is not entirely clear with positive,
negative, and null findings prevalent in the literature
(Michopoulos et al, 2017). Among women with severe
anxiety, we observed reduced serum levels of IL-18 which
corroborates a hypothesis of reduced IL-18 due to disregu-
lated reactive oxygen species-related metabolism in patients
suffering from trauma (Segman et al, 2005). Polymorphisms
in this member of the IL-1 superfamily were shown to be
predictive of depression and anxiety through altered
amygdala reactivity of threat perception in women but not
in men (Swartz et al, 2017). While the role of ASB family
members is not well described (Chung et al, 2005), one
family member ASB3 has been shown to regulate responses
to the pro-inflammatory cytokine tumor necrosis factor
(TNF)-alpha by mediating the degradation of its receptor
TNF-R2 (Chung et al, 2005) and its gene expression is
downregulated in colorectal cancer (Du et al, 2017). The
impact of stress-induced Asb1 expression on peripheral
inflammation was further supported in our mouse model,
where we observed strong correlation of Asb1 expression
with expression of the IL-1B gene. The inflammasome, a
multiprotein component of innate immune responses, is
suggested to be a key mediator of physiologic and
psychological stressors by way of its activation of IL-1β
and IL-18, which are involved in neuroinflammation and
neurodegeneration (Wong et al, 2016). Thus, altered
regulation of Asb1 may impact inflammatory pathways, but
whether these peripheral effects are a cause, effect, or
epiphenomenon of anxiety phenotypes remains to be
examined by future studies.
One of the main risk factors for anxiety disorders are
adverse life events. We wanted to assess whether Asb1 is
regulated by such environmental risk factors and therefore
measured its expression using a mouse model of social defeat
stress. These translational studies demonstrated that acute
stress response resulted in significant upregulation of the Asb1
gene transcript in peripheral blood of socially defeated mice
compared to controls, 4 h after stress exposure. Together our
results may suggest that Asb1 transcription is altered in the
acute stress response, as evidenced by the murine model, and
that differences in the DNA methylation of that locus are
associated with maladaptive stress response conditions in
human cohorts. Whether the changes are causally related or
the consequence of anxiety disorders cannot be resolved in
this study. While this is the first study to identify a role for
Asb1 in anxiety disorders, evidence for a role of this relatively
unknown gene in other areas of mental health have been
demonstrated, for example, in a de novo mutation in
individuals with autism spectrum disorder (Neale et al, 2012).
Our results contribute to a few other studies that have
identified epigenetic modifications associated with common
mood disorders in clinical and smaller population-based
settings (El-Sayed et al, 2012). One study of panic disorder
Table 4 Least-Squares Mean of CRP and IL-18 in Severe vs no Anxiety Categories Stratified by Sex in KORA F4
Men Women
N LS-mean 95% confidence
limits
p-Value N LS-mean 95% confidence
limits
p-Value
CRP (mg/l)
No/minimal anxiety 489 2.25 1.94 2.57 437 2.50 2.18 2.82
Severe anxiety 12 3.17 1.14 5.21 0.79 10 2.55 0.41 4.69 0.28
No/minimal anxiety 486 349.83 337.38 361.87 436 293.90 276.36 311.44
Severe anxiety 12 381.30 305.11 459.50 0.38 10 229.29 112.92 345.67 0.03
The least-squares (LS) mean of CRP or IL-18 was calculated by generalized linear models adjusted for age, BMI, smoking status and alcohol consumption. p-Values were
generated using log-transformed measurements and results are reported with levels transformed back to the original scale. The least-squares mean difference that was
statistically significant at po0.05 is indicated in bold.
Figure 2 Scatter plot of the correlation between PAS scores in the MPIP
cohort (n= 131) and methylation levels of cg12701571. The regression line
and 95% confidence intervals are depicted with the continuous black line
and gray shade, respectively.
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patients (n= 36) has identified reduced function of the
noradrenaline transporter (NET) due to increased methyla-
tion of the promoter region of this gene (Bayles et al, 2013).
A number of genes involved in the innate and adaptive
immune system were shown to be differentially methylated
between 23 individuals suffering from post-traumatic stress
disorder from the Detroit Neighborhood Health Survey and
77 without PTSD (Uddin et al, 2010). A comparison of 50
participants with lifetime PTSD and 60 control participants
demonstrated decreased methylation of a neurotransmitter
in the opioid system which is also associated with
inflammatory pain (Smith et al, 2011). Finally, a small
epigenetic study (n= 25 anxious and n= 22 non-anxious
individuals) showed a relationship between anxiety, epige-
netics, and interleukin 6 (IL-6) (Murphy et al, 2015). Taken
together, these data add to the mounting evidence of
immunologically distinct mechanisms that may underlie
pathogenesis of distress-related disorders and contribute
population-based insight into epigenetic mechanisms that
may contribute to the social threat hypothesis of anxiety,
inflammation, and depression (Camacho, 2013; Slavich and
Irwin, 2014).
Limitations and Strengths
The main analysis used data from a population-based study.
Individuals are influenced by many different environmental
factors and are not subject to specific control criteria. Thus, it
is remarkable to find DNA methylation profiles associating
with severe anxiety. We showed that applying an EWAS
approach to population studies can provide evidence for
epigenetic mechanisms that might be connected to distress-
related diseases. The interpretation of results from blood-
based EWAS, in the case of genes involved with immune
responses is challenged by the concern that observations may
be driven by the cellular composition of the blood samples
obtained. The inclusion of cell count estimates in our
adjusted analyses is a standard approach used to minimize
this bias. Because of the cross-sectional design of this study,
we are unable to draw conclusions about the causal nature of
the associations observed.
The present study utilized two different questionnaires
(GAD-7 and PAS) to measure anxiety symptoms in the
included cohorts. To our knowledge, there are no studies
examining the correlation between the two questionnaires,
and GAD-7 was not available in the MPIP study which is a
study focusing on panic symptomatology. The GAD-7
instrument fulfills the criteria of the DSM-5 classification
criteria of the American Psychiatric Association, is a good
indicator of anxiety symptom severity (Beard and
Björgvinsson, 2014), and has a strong overlap with panic
disorder (Kroenke et al, 2007). While the approach of using
different questionnaires has inherent limitations, GAD-7 and
PAS are comparable to the extent that both questionnaires
interrogate the common underlying construct of anxiety.
Furthermore, hypermethylation in the Asb1 gene was also
observed with increasing symptom severity in patients with
anxiety disorders which suggests a dose response of stress
induced epigenetic changes. Our sampling population was
composed of Caucasians of European ancestry, so the
generalizability of these results to other ethnicities requires
further investigation. The small number of cases (n= 22
individuals with severe anxiety in the discovery study
(KORA F4) vs n= 961 controls) may have limited the
number of significant hits we could identify; nonetheless, our
epidemiologic discovery was supported by comparable
association in a larger clinical sample of patients, and other
published studies of methylation and stress disorders noted
above have reported similarly small case samples as our
discovery cohort.
Finally, we acknowledge that the differences in study
design and cohorts preclude our ability to establish a
replication of our epidemiologic finding; however, the
supporting clinical study demonstrated that the Asb1 gene
is epigenetically modified by more than one fear-associated
disorder. Our aim in translating these results into a mouse
model was to gain mechanistic insight by examining whether
the Asb1 gene is stress regulated, with tissue specificity and
functional consequences. Overall, we find the evidence
provided warrants future study to further characterize the
contribution of epigenetic changes in this relatively unknown
gene region that may contribute to inflammatory alterations
in fear-based disorders.
CONCLUSIONS
The present study suggests that the Asb1 gene is responsive
to stress exposure and epigenetically modified by anxiety
phenotypes. While future studies need to mechanis-
tically dissect the functional relationship between Asb1
methylation and expression and inflammatory consequences
in the context of both acute and chronic anxiety, our data
suggest that the altered regulation of Asb1 in response to
acute stress is specific for peripheral blood and may be
relevant for changes in levels of peripheral inflammation.
This adds to the mounting evidence of immunologically
distinct mechanisms that may underlie pathogenesis of
stress-related disorders. Further studies are warranted to
characterize the pathogenetic role of Asb1 in anxiety
disorders.
Figure 3 Box plots of Asb1 gene expression levels (represented by the
ILMN_2430887 probe) detected in mouse blood after social defeat
exposure (n= 9) or control conditions (n= 7). Values in the y axis are
presented as batch-corrected residuals.
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